Elevara Medicines appointed Dr. Mai-Britt Zocca as CEO, succeeding founder Emma Tinsley who will remain on the board. Dr. Zocca brings extensive biotech leadership experience, having led Nasdaq-listed IO Biotech through advanced clinical trials. Elevara is developing ELV001, a novel oral treatment for rheumatoid arthritis currently in Phase 2b trials, aiming to improve outcomes for patients with inadequate responses to existing therapies. The company recently raised $70 million to fund this development and plans to advance ELV001 as a new treatment option targeting disease mechanisms beyond immune modulation.
FREELANDER, a British premium automotive brand co-developed by Chery and Jaguar Land Rover, announced its first international market launch in Abu Dhabi, UAE, scheduled for September 2026. This launch marks a key milestone in the brand's global expan...
The global crypto market fell about 1.5% with Bitcoin dropping below $62,000 due to renewed Middle East tensions and macroeconomic concerns. Investor sentiment worsened, reflected by a drop in the Fear & Greed Index to 'Extreme Fear.' Institutional i...
Munters Group AB is repositioning its business to prioritize Data Center Technologies (DCT), which is expected to become its largest segment, surpassing AirTech. The company is considering divesting its FoodTech division, potentially raising $180–370...
The Trade Desk (TTD) stock has dropped 62% since the last coverage, yet the analyst maintains a strong buy rating. Trading at about 11 times forward price-to-earnings, TTD appears undervalued given its double-digit revenue growth, strong data advanta...
Amazon is currently rated a strong buy due to its historically low price-to-operating cash flow ratio despite solid fundamentals. Key growth drivers include its AWS and Advertising segments, which are the fastest-growing and highest-margin parts of t...
